{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T21:18:19Z","timestamp":1773350299403,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1002\/jps.21197","type":"journal-article","created":{"date-parts":[[2007,9,19]],"date-time":"2007-09-19T17:47:09Z","timestamp":1190224029000},"page":"2552-2567","source":"Crossref","is-referenced-by-count":33,"title":["A Biophysical Characterization of the Peptide Drug Pramlintide (AC137) Using Empirical Phase Diagrams"],"prefix":"10.1016","volume":"97","author":[{"given":"Akihisa","family":"Nonoyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer S.","family":"Laurence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liza","family":"Garriques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thao","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.Russell","family":"Middaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1002\/jps.21197_bb0010","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0031-3955(16)34604-1","article-title":"Etiology and pathogenesis of diabetes mellitus","volume":"31","author":"Lebovitz","year":"1984","journal-title":"Pediatr Clin North Am"},{"key":"10.1002\/jps.21197_bb0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000080503","article-title":"b-Cells in type 2 diabetes: A loss of function and mass","volume":"62","author":"Maedler","year":"2004","journal-title":"Horm Res"},{"key":"10.1002\/jps.21197_bb0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1568005310202010063","article-title":"Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus","volume":"2","author":"Baron","year":"2002","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"10.1002\/jps.21197_bb0025","doi-asserted-by":"crossref","first-page":"744","DOI":"10.2337\/diacare.19.7.744","article-title":"The medical management of hyperglycemia over a 10-year period in people with diabetes","volume":"19","author":"Klein","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1002\/jps.21197_bb0030","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1073\/pnas.84.23.8628","article-title":"Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients","volume":"84","author":"Cooper","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/jps.21197_bb0035","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/BF00401833","article-title":"Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin","volume":"38","author":"Young","year":"1995","journal-title":"Diabetologia"},{"key":"10.1002\/jps.21197_bb0040","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0029-1211958","article-title":"The role of amylin in the physiology of glycemic control","volume":"106","author":"Scherbaum","year":"1998","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1002\/jps.21197_bb0045","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/0031-9384(95)02067-5","article-title":"Amylin decrease meal size in rats","volume":"58","author":"Lutz","year":"1995","journal-title":"Physiol Behav"},{"key":"10.1002\/jps.21197_bb0050","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/14746514050050030701","article-title":"Amylin analogue as an antidiabetic agent","volume":"5","author":"Day","year":"2005","journal-title":"Br J Diabetes Vasc Dis"},{"key":"10.1002\/jps.21197_bb0055","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0950-351X(88)80034-X","article-title":"Role of insulin resistance in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus","volume":"2","author":"Gerich","year":"1988","journal-title":"Bailliere's Clin Endocrinol Metabolism"},{"key":"10.1002\/jps.21197_bb0060","first-page":"493","article-title":"High affinity amylin binding sites in rat brain","volume":"44","author":"Beaumont","year":"1993","journal-title":"Mol Pharmacol"},{"key":"10.1002\/jps.21197_bb0065","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1016\/S0021-9258(19)39539-0","article-title":"Islet amyloid polypeptide. A new b cell secretory product related to islet amyloid deposits","volume":"265","author":"Nishi","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1002\/jps.21197_bb0070","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0140-6736(87)90825-7","article-title":"Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes","volume":"2","author":"Clark","year":"1987","journal-title":"Lancet"},{"key":"10.1002\/jps.21197_bb0075","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1006\/jmbi.1999.2646","article-title":"Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro","volume":"287","author":"Kayed","year":"1999","journal-title":"J Mol Biol"},{"key":"10.1002\/jps.21197_bb0080","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1073\/pnas.87.13.5036","article-title":"Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation","volume":"87","author":"Westermark","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/jps.21197_bb0085","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1006\/jsbi.2000.4268","article-title":"Amyloid fibril formation from full-length and fragments of amylin","volume":"130","author":"Goldsbury","year":"2000","journal-title":"J Struct Biol"},{"key":"10.1002\/jps.21197_bb0090","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0968-0004(90)90015-4","article-title":"The role of amylin in the insulin resistance of non-insulin-dependent diabetes mellitus","volume":"15","author":"Leighton","year":"1990","journal-title":"Trends Biochem Sci"},{"key":"10.1002\/jps.21197_bb0095","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jmb.2005.02.029","article-title":"The parallel superpleated beta-structure as a model for amyloid fibrils of human amylin","volume":"348","author":"Kajava","year":"2005","journal-title":"J Mol Biol"},{"key":"10.1002\/jps.21197_bb0100","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0167-4889(89)90220-6","article-title":"Amylin and the amylin gene: Structure, function and relationship to islet amyloid and to diabetes mellitus","volume":"1014","author":"Cooper","year":"1989","journal-title":"Biochim Bbiophys Aacta"},{"key":"10.1002\/jps.21197_bb0105","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2174\/1381612013397357","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improved metabolic control","volume":"7","author":"Weyer","year":"2001","journal-title":"Curr Pharm Des"},{"key":"10.1002\/jps.21197_bb0110","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2165\/00003495-200464130-00003","article-title":"Pramlintide for the treatment of insulin-requiring diabetes mellitus: Rationale and review of clinical data","volume":"64","author":"Kruger","year":"2004","journal-title":"Drugs"},{"key":"10.1002\/jps.21197_bb0115","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/meta.2002.32022","article-title":"The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes","volume":"51","author":"Fineman","year":"2002","journal-title":"Metabolism"},{"key":"10.1002\/jps.21197_bb0120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/15209150252924094","article-title":"Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes","volume":"4","author":"Ratner","year":"2002","journal-title":"Diabetes Technol Ther"},{"key":"10.1002\/jps.21197_bb0125","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1345\/aph.1C387","article-title":"Pramlintide for the treatment of diabetes mellitus","volume":"37","author":"Kleppinger","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1002\/jps.21197_bb0130","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.2337\/diabetes.53.suppl_3.S233","article-title":"Amylin agonists: A novel approach in the treatment of diabetes","volume":"53","author":"Schmitz","year":"2004","journal-title":"Diabetes"},{"key":"10.1002\/jps.21197_bb0135","doi-asserted-by":"crossref","first-page":"19478","DOI":"10.1074\/jbc.M603313200","article-title":"Conformational stability and disassembly of Norwalk virus-like particles. Effect of pH and temperature","volume":"281","author":"Ausar","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1002\/jps.21197_bb0140","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/mp0500465","article-title":"Analysis of the thermal and pH stability of human respiratory syncytial virus","volume":"2","author":"Ausar","year":"2005","journal-title":"Mol Pharm"},{"key":"10.1002\/jps.21197_bb0145","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/jps.20410","article-title":"Solution behavior of IFN-b-1a: An empirical phase diagram based approach","volume":"94","author":"Fan","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21197_bb0150","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jps.20484","article-title":"Anthrax vaccine powder formulations for nasal mucosal delivery","volume":"95","author":"Jiang","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21197_bb0155","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/jps.10439","article-title":"Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: A bGCSF case study","volume":"92","author":"Kueltzo","year":"2003","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21197_bb0160","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jps.20496","article-title":"Effect of pH and ionic strength on the physical stability of adenovirus type 5","volume":"95","author":"Rexroad","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21197_bb0165","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/jps.20621","article-title":"Biophysical characterization of polymeric and liposomal gene delivery systems using empirical phase diagrams","volume":"95","author":"Ruponen","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21197_bb0170","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1110\/ps.062133706","article-title":"Probing protein structure and dynamics by second-derivative ultraviolet absorption analysis of cation-{pi} interactions","volume":"15","author":"Lucas","year":"2006","journal-title":"Protein Sci"},{"key":"10.1002\/jps.21197_bb0175","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jps.10440","article-title":"Structural characterization of bovine granulocyte colony stimulating factor: Effect of temperature and pH","volume":"92","author":"Kueltzo","year":"2003","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21197_bb0180","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1006\/jmbi.1998.2365","article-title":"Hydrogen exchange in ribonuclease A and ribonuclease S: Evidence for residual structure in the unfolded state under native conditions","volume":"285","author":"Neira","year":"1999","journal-title":"J Mol Biol"},{"key":"10.1002\/jps.21197_bb0185","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1021\/bi00752a003","article-title":"Primary structure effects on peptide group hydrogen exchange","volume":"11","author":"Molday","year":"1972","journal-title":"Biochemistry"},{"key":"10.1002\/jps.21197_bb0190","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/prot.340170110","article-title":"Primary structure effects on peptide group hydrogen exchange","volume":"17","author":"Bai","year":"1993","journal-title":"Proteins"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916326065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916326065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:24:53Z","timestamp":1629764693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916326065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S0022354916326065"],"URL":"https:\/\/doi.org\/10.1002\/jps.21197","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}